title: [Cyclosporin A in atopic dermatitis].
abstract: Atopic dermatitis is a chronic inflammatory skin disease, with inherited predisposition. It has typical morphology and distribution. Patients generally can be controlled with the use of moisturizers and topical steroids. In severe cases, it is recommended the use of alternative management. Cyclosporine is an immunosuppressor drug which inhibit the expression of T activated cells. Many open and placebo-controlled trials have been made evaluating its use, efficacy and security, in adults and children. The results suggest an initial dose of 5-6 mg/kg per day and reducing the amount according to response (load dose and maintenance dose) at long term in order to reach complete remission after withdrawal of treatment and limit adverse effects, like renal toxicity and hypertension. The immunological changes in AD patients treated with cyclosporine include eosinophil count reduction, besides lower levels of E-selectin, and soluble CD30 (known as disease markers), but overall, it corrects the imbalance between Th1 and Th2 response present in these kinds of diseases.
authors.affiliation: Servicio de alergia, Médico pediatra, Hospital Infantil de México Federico Gómez, México, DF.
authors.forename: Miguel Angel
authors.initials: MA
authors.lastname: Cordero Miranda
authors.forename: Begonia
authors.initials: B
authors.lastname: Casas Becerra
authors.forename: Norma Isabel
authors.initials: NI
authors.lastname: Reyes Ruiz
authors.forename: Lourdes
authors.initials: L
authors.lastname: Avila Castañón
authors.forename: Blanca Estela
authors.initials: BE
authors.lastname: del Río Navarro
authors.forename: Juan José Luis
authors.initials: JJ
authors.lastname: Sienra Monge
mesh_terms: D000328:Adult; D002648:Child; D002986:Clinical Trials as Topic; D016572:Cyclosporine / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D016207:Cytokines / Q000378:metabolism; D003876:Dermatitis, Atopic / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D007674:Kidney Diseases / Q000139:chemically induced; D008213:Lymphocyte Activation / Q000187:drug effects; D015337:Multicenter Studies as Topic; D013601:T-Lymphocytes / Q000187:drug effects
chemical_list: D016207:Cytokines; D007166:Immunosuppressive Agents; D016572:Cyclosporine